This $196,875 project grant awarded by the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 "Drug Use and Addiction Research Programs" is supporting research on the development of tetrahydrocannabivarin (THCV) as a treatment for smoking cessation. The University of California, Los Angeles (UCLA) is conducting a human clinical trial to assess the efficacy of THCV in reducing smoking behaviors, cravings, and withdrawal symptoms in daily smokers. The study involves a randomized, double-blind, crossover design with 32 participants completing two outpatient visits after receiving either THCV or a placebo. Key outcomes to be measured include the ability to resist smoking, cigarette self-administration, subjective craving, withdrawal, and nicotine effects. This research aims to provide initial evidence on the therapeutic potential of THCV, a naturally occurring cannabinoid, as a novel treatment approach for nicotine dependence and smoking cessation. The project period runs from August 2024 to July 2026.
Generated 2/25/25, 3:05 AM